Tango Therapeutics (NASDAQ: TNGX) legal chief resigns effective Sept. 12, 2025

Rhea-AI Filing Summary

Tango Therapeutics, Inc. reported that Douglas Barry has resigned from his roles as Chief Legal and Compliance Officer and Corporate Secretary. He notified the board of directors on August 21, 2025, and his resignation will be effective as of September 12, 2025. The company states that he is leaving to pursue another opportunity.

false 0001819133 0001819133 2025-08-21 2025-08-21

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): August 21, 2025

TANGO THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39485		47-2452488
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

201 Brookline Avenue

Suite 901

Boston, MA 02215

(Address of principal executive offices, including zip code)

Registrant’s telephone number, including area code: 857-320-4900

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.001 per share		TNGX		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 21, 2025, Douglas Barry notified the board of directors of Tango Therapeutics, Inc. (the “Company”) of his resignation as Chief Legal and Compliance Officer and Corporate Secretary of the Company, in each case, effective as of September 12, 2025, to pursue another opportunity.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 25, 2025

TANGO THERAPEUTICS, INC.
By:		/s/ Daniella Beckman
Name:		Daniella Beckman
Title:		Chief Financial Officer

FAQ

What leadership change did Tango Therapeutics (TNGX) disclose?

Tango Therapeutics disclosed that Douglas Barry resigned as its Chief Legal and Compliance Officer and Corporate Secretary, effective September 12, 2025.

When did Tango Therapeutics (TNGX) receive Douglas Barry’s resignation?

The board of directors was notified of Douglas Barry’s resignation on August 21, 2025.

What positions did Douglas Barry hold at Tango Therapeutics (TNGX)?

Douglas Barry served as Chief Legal and Compliance Officer and Corporate Secretary of Tango Therapeutics.

Why is Douglas Barry leaving Tango Therapeutics (TNGX)?

The company states that Douglas Barry is resigning to pursue another opportunity.

When does Douglas Barry’s resignation at Tango Therapeutics (TNGX) become effective?

His resignation is effective as of September 12, 2025.

Who signed the Tango Therapeutics (TNGX) report about this leadership change?

The report was signed on behalf of Tango Therapeutics by Daniella Beckman, the company’s Chief Financial Officer.